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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
A dual role for integrin-linked kinase in platelets: regulating integrin function and
-granule secretion
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Integrin-linked kinase (ILK) has been im-
plicated in the regulation of a range of
fundamental biological processes such
as cell survival, growth, differentiation,
and adhesion. In platelets ILK associates
with 1- and 3-containing integrins,
which are of paramount importance for
the function of platelets. Upon stimula-
tion of platelets this association with the
integrins is increased and ILK kinase
activity is up-regulated, suggesting that
ILK may be important for the coordination
of platelet responses. In this study a
conditional knockout mouse model was
developed to examine the role of ILK in
platelets. The ILK-deficient mice showed
an increased bleeding time and volume,
and despite normal ultrastructure the
function of ILK-deficient platelets was
decreased significantly. This included re-
duced aggregation, fibrinogen binding,
and thrombus formation under arterial
flow conditions. Furthermore, although
early collagen stimulated signaling such
as PLC2 phosphorylation and calcium
mobilization were unaffected in ILK-
deficient platelets, a selective defect in
-granule, but not dense-granule, secre-
tion was observed. These results indicate
that as well as involvement in the control
of integrin affinity, ILK is required for
-granule secretion and therefore may
play a central role in the regulation of
platelet function. (Blood. 2008;112:
4523-4531)
Introduction
Integrin-linked kinase (ILK) was originally identified and cloned in
1996 as the result of a 2-hybrid screen for 1-integrin–interacting
proteins1 and is present in many tissues including heart, placenta,
liver, kidney, pancreas,1 and platelets.2 Originally recognized for its
ability to regulate integrin-mediated signal transduction, ILK has
subsequently been shown to be involved in normal cardiac
function,3,4 cardiac-hypertrophy,5,6 hepatocyte differentiation,7 den-
drite formation,8 bone development,9 and several types of cancer.10-12
The structural characterization of this 59-kDa cytosolic protein
implicates ILK in the coordination of cell signaling through its
potential to interact directly and indirectly with receptors, cytoso-
lic-signaling proteins, and cytoskeletal proteins across its 3 structur-
ally conserved domains.1 The C terminus of ILK contains a
serine-threonine kinase domain that binds to 1- and 3-containing
integrins, parvin, paxillin (Hic5), kindlin (UNC-112 or MIG2) and
PDK1.2,13-15 Adjacent to this is a pleckstrin homology domain that
binds to phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3).16
The binding of PtdIns(3,4,5)P3 is thought to regulate kinase activity
and facilitates interaction with -parvin, which supports the
formation of focal adhesions.13,17 At the N terminus of this
molecule 4 ankyrin repeats bind to both ILK-associated phospha-
tase (ILKAP) and particularly interesting new cystine-histidine
protein (PINCH).18-25 These interactions with integrins, intercellu-
lar signaling complexes and matrix proteins link the structural
frameworks of the extracellular matrix (ECM) and the cytoskeleton
and allow the transmission of bidirectional signals.26
Debate has surrounded whether the cellular role of ILK
involves kinase activity. Work in ILK-deficient murine endothelial
cells and in HEK-293 cells, using siRNA to silence ILK expression,
has demonstrated that ILK has a role in the phosphorylation of
protein kinase B (PKB)/Akt at Ser473.27,28 This was confirmed by
coimmunoprecipitation, mass spectrometry, and mutational analy-
sis.29 The sequence of the kinase domain, however, is not well
conserved between species,18 with sequence differences to other
serine/threonine kinases found in the catalytic loop and conserved
DXG motif.30 In some systems kinase dead mutations are still able
to function or rescue function in ILK-deficient cells,26,31 and in
ILK-deficient mouse fibroblasts PKB phosphorylation is unaf-
fected.31 These discrepancies may underscore cell-specific and
potentially species-specific differences in the mechanisms through
which ILK contributes to cell function.
Platelets play a fundamental role in hemostasis. Upon injury
they become exposed to subendothelial matrix proteins, particu-
larly collagens, to which they initially adhere via the GPIb-V-IX
complex and plasma von Willebrand factor (VWF). This interac-
tion with collagen is stabilized via direct interactions between
platelet collagen receptor glycoprotein VI (GPVI) and integrin
21. The binding of collagen to GPVI and receptor clustering
results in the tyrosine phosphorylation of the FcR -chain and
triggers a signaling pathway that leads to PLC2 phosphorylation
and calcium mobilization.32 At sites of injury platelets are also
exposed to thrombin generated due to the activation of the
coagulation pathways, resulting in platelet signaling through the
protease-activated receptors, PAR1 (PAR3 in mouse), and PAR4.33
Both signaling pathways result in cell spreading, positive feedback
signaling, and signaling to other platelets. The latter occurs via
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secretion of thrombotic factors and inside-out integrin signaling,
through which the affinity of integrins 21 and IIb3 become
increased. The bivalent binding of fibrinogen to integrin IIb3
supports platelet-platelet adhesion and hence thrombus formation.
The resulting thrombus is stabilized by the increasing affinity of
21 for collagen.34
Platelets depend upon integrins for their role in hemostasis, as
demonstrated by conditions where expression is reduced, such as
Glanzmann thrombocytopenia.35 Through inside-out and outside-in
signaling the integrins mediate a variety of cellular processes36 and
are important in transduction pathways linking extracellular adhe-
sive proteins (such as VWF, fibrinogen, and collagen), with
intracellular signaling molecules (such as focal adhesion kinase
[FAK] and paxillin) and cytoskeletal components (including talin,
filamin, and -actinin37,38).
In this study a conditional ILK-deficient mouse model was used
to examine the role of ILK in the regulation of platelet function,
signaling, and thrombus formation under arterial flow conditions.
The data indicate an important role for this molecule in the control
of platelet biology.
Methods
Reagents
Collagen-related peptide (CRP), a GPVI-selective agonist was synthesized
by Pepceuticals LTD (Nottingham, United Kingdom) and chemically
cross-linked.39 Horm-Chemie collagen (collagen fibers from equine ten-
dons) was purchased from Nycomed (Munich, Germany) and thrombin
from Sigma (Poole, United Kingdom). Antibodies for immunoblotting:
anti-ILK (C-19, sc-7516), anti-2 (N-19, sc-6586), anti-IIb (C-20, sc-
6602), anti-1 (N-20, sc-6622), anti-3 (C-20, sc-6602), anti-PINCH1
(N-19, sc-47 914), anti-talin (C-20, sc-7534), and anti-PLC2 (Q-20,
sc-407) were purchased from Santa Cruz Biotechnology (Autogenbioclear;
Calne, United Kingdom). Anti–P-selectin (RB40.34) was supplied by BD
Biosciences, anti-phosphotyrosine (4G10) by Upstate (Millipore, Watford,
United Kingdom), and anti-GAPDH (6C5), anti-kindlin polyclonal
(ab36957), and anti-parvin alpha (ab11336) by AbCam (Cambridge, United
Kingdom). For flow cytometry phycoerythrin (PE)–labeled CD62P (P-
selectin) and fluorescein isothiocyanate (FITC) anti-mouse CD41 (integrin
IIb) were purchased from BD Biosciences. FITC-labeled fibrinogen was
produced by incubating fibrinogen (2.5 mg/5 mL in phosphate-buffered
saline [PBS]) in the dark with FITC (1 mg/mL in acetonitrile) in the
presence of reaction buffer (PBS with 0.1% SDS, 1% triethylamine at pH 9)
in a 1:1:1 ratio. The solution was gently mixed at 65°C in the dark for
30 minutes, and FITC-labeled fibrinogen then purified by ultrafiltration.
Reagents used for the platelet factor 4 assay include: anti-rabbit (whole
molecule)–peroxidase (Sigma A6154), rabbit anti–human platelet factor 4
(AYNRHPF4; Accurate Chemical & Scientific, Westbury, NY) and 3,3,5,5-
tetramethyl-benzidine (TMB) was from Sigma. The chemiluminescent
Western blotting substrate was supplied by Pierce (Perbio, Cramlington,
United Kingdom) and x-ray film by GE Healthcare (Little Chalfont, United
Kingdom). Densitometry was performed using a BIO-RAD GS-710
calibrated imaging densitometer, and Quantity One analysis software.
Fluo-4AM was from Invitrogen (Fisher Scientific, Loughborough, United
Kingdom).
Generation of mice
LoxP-flanked ILK-transgenic mice3,9,27 were crossed with mice containing
a Cre transgene under control of the Mx1 promoter. Founders and breeding
stock were backcrossed onto the C57BL6 genetic background and litters
were genotyped by polymerase chain reaction (PCR) to select ILK(lox/lox):
MxCre31 mice and littermate ILK(/):MxCre (control [Ctrl]) mice. All
mice were given an intraperitoneal injection of 300 g Poly(I)-Poly(C)
(pIpC) 8 days prior to experiments.
Preparation and aggregation of washed platelets
Blood was obtained from KO (ILK(lox/lox):MxCre) and control
(ILK(/):MxCre) litter-matched mice via cardiac puncture following
termination. Blood (1 mL) was drawn into a syringe containing acidic
citrate dextrose (100 L) (ACD; 120 mM sodium citrate, 110 mM glucose,
80 mM citric acid) as anticoagulant. Platelets were prepared from whole
blood by differential centrifugation in the presence of prostacyclin (0.1 g/
mL) and resuspended in modified Tyrode-HEPES buffer (134 mM NaCl,
0.34 mM Na2HPO4, 2.9 mM KCl, 12mM NaHCO3, 20 mM HEPES, 5 mM
glucose, 1 mM MgCl2, pH 7.3) to a density of 8  108 cells/mL and rested
for 30 minutes at 30°C prior to experiments. Platelets (90 L) were
stimulated with collagen at 37°C with continuous stirring (1200 rpm) in an
optical aggregometer for 90 seconds. For aggregation experiments in
platelet-rich plasma (PRP), blood was taken into citrate (3.13% [wt/vol]).
PRP was collected and control and KO samples matched for platelet
number (at a density no less than 2  108) and stimulated with collagen at
37°C with continuous stirring (1200 rpm) in an optical aggregometer. All
protocols involving the use of animals were approved by the University of
Reading Local Ethical Review Panel and are authorized by a United
Kingdom Home Office License.
Immunoblotting and immunoprecipitation
Immunoprecipitation, SDS-PAGE, and immunoblotting onto polyvinyli-
dine difluoride membrane were all performed using standard techniques.40
Densitometry was performed using GAPDH levels to normalize for protein
loading.
Flow cytometry
Surface integrin IIb3 levels were assessed with anti-IIb (CD61)
antibody and fibrinogen binding was measured using FITC-labeled fibrino-
gen. Surface exposure of P-selectin was observed as a measure of -granule
secretion using a PE-conjugated anti-CD62P (P-selectin) antibody. Flow
cytometry was carried out on a FACScan system and analyzed using
CellQuest software (Becton Dickinson, Oxford, United Kingdom).
Dense granule secretion
Platelets (8  108 cells/mL) were loaded with [3H] 5-HT (37 kBq/mL) by
incubation in PRP for 1 hour at 30°C. [3H] 5-HT secretion following
activation was measured by scintillation spectrometry.41
-granule secretion: assay for platelet factor 4 (PF4)
Forty microliters of washed platelets at a density of 4  108 were
stimulated with collagen (10 g/mL) or thrombin (5 units/mL) for
90 seconds and stopped with 5 L of 6% glutaraldehyde, then immediately
centrifuged. Ten microliters of supernatant of lysed (maximum), resting and
stimulated platelets were added in triplicate to 96-well plates containing
100 L of binding buffer (50 mM 3-[cyclohexylamino]-1-propanesulfonic
acid [CAPS] at pH 11.5). After incubating for 2 hours the plate was washed
twice with wash buffer (0.165 mM Na2HPO4, 0.035 mM NaH2PO4, 1.5 mM
NaCl) then blocked with 5% dried skimmed milk in TBS for 30 minutes.
One hundred microliters of antiplatelet factor 4 antibody (10 ng/mL) was
added to the wells for 1 hour and after 2 washes, 1:500 dilution of
anti-rabbit peroxidase was added for 1 hour. Plates were washed 3 times and
developer (3,3,5,5-tetramethyl-benzidine [TMB] in 40% methanol and
0.015% H2O2) was added, color was allowed to develop for 15 minutes
before 50 L HCl (1 M) was added, and the plate was read at 450 nm on a
Molecular Devices Emax precision microplate reader.
Intracellular calcium mobilization analysis
Fluo-4AM was added to murine PRP, prepared from whole blood by
centrifugation, at a final concentration of 10 M and incubated for
45 minutes at 30°C. Platelets were centrifuged and resuspended in Tyrode
as normal and rested for 30 minutes. Fifty microliters of washed platelets
were added to 96-well black-walled, clear-bottom microtiter plates (Greiner
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Bio-One, Frickenhausen, Germany). The plate was loaded into a Flexsta-
tion (Molecular Devices, Wokingham, United Kingdom) and allowed to
equilibrate to temperature (37°C). CRP was then added to the plate to give
10 g/mL final concentration (sufficient to stimulate full aggregation).
Settings were: excitation 488 nm, emission 525 nm, reading sensitivity
“normal,” and photomultiplier tube (PMT) sensitivity “high.” Run time was
180 seconds, with a fluorescence reading taken every 1.4 seconds. Analysis
was performed using Softmax Pro software (Molecular Devices).
Thrombus formation in whole blood under arterial flow
conditions
Platelets in whole blood were loaded with the lipophilic fluorescent dye
3,3-dihexyloxacarbocyanine iodide (DiOC6; 0.5 ng/mL final) in 50%
ethanol (0.05% [vol/vol] final) in the dark at room temperature for 30
minutes prior to perfusion. This had no effect on platelet aggregation (not
shown), consistent with other reports.42 Whole blood was perfused through
a collagen-coated (100 g/mL) glass microcapillary using a syringe pump
at a shear rate of 1000 s1. Twenty microliters of Tyrode-HEPES buffer was
then perfused though the system to remove unattached cells. The capillary
was transferred to a Leica DMIRE2 inverted confocal microscope, and
images were collected at room temperature through the thrombi at 2-m
intervals in the Z-plane (using N PLANL 20  0.4 objective lens with 0-2
mm correction) within 5 randomly selected fields of view. The resulting
Z-stack data were analyzed using TCS SP2 software (Leica, Milton Keynes,
United Kingdom) to calculate thrombus depth. t tests were performed using
Microsoft Excel after confirming normality using SPSS software. Results
are presented as mean values plus or minus standard error of the mean.
P values of less than .05 were considered significant.
Tail-bleeding assay
Mice were anesthetized using ketamine (80 mg/kg) and xylazine (5 mg/kg)
administered via the intraperitoneal route and placed on a heated mat. One
millimeter of tail tip was removed using a scalpel blade and the tail tip
bathed in sterile saline at 37°C. The time to cessation of bleeding was
measured up to 10 minutes, after which the assay was terminated.
Transmission electron microscopy
Washed platelets were dually fixed with glutaraldehyde and osmic acid
adapted from a method described by White.43 In summary, an equal volume
of 0.1% glutaraldehyde in White saline was added to washed platelets in
Tyrode buffer for 15 minutes at room temperature (RT), after which
platelets were centrifuged at 800g for 5 minutes then resuspended in 0.3%
(vol/vol) glutaraldehyde for 45 minutes at RT. Platelets were then washed in
White saline (0.7% NaCl [wt/vol], 0.0375% KCl [wt/vol], 0.05% MgSO4
[wt/vol], 0.075% Ca[NO3]2 4H2O [wt/vol], 0.055% NaHCO3 [wt/vol],
0.01% Na2HPO4  7H2O [wt/vol], 0.003% KH2PO4 [wt/vol], trace Phenol
red) and resuspended in 1% (wt/vol) osmium for 1 hour. Samples were then
dehydrated by a graded series of acetone and embedded in EPON resin
made as per the manufacturer’s instructions (Agar; Stansted, United
Kingdom). Sections of approximately 0.7 m were produced and floated
onto a formvar film strengthened with carbon, then stained with lead citrate
for 15 minutes, washed in water, and observed on a Philips CM20 analytical
TEM at ambient temperature, 80 kV and 25 K true magnification. The
imaging medium was Kodak Electron image film, SO-163.
Results
Production of conditional ILK-deficient mice
The association of ILK with the integrins 21 and IIb3 suggest
that ILK may have a role in platelet function.32 The systemic
deletion of the ILK gene is embryonically lethal in mice at 3 to
5 days’ gestation.31 Therefore, a conditional deletion model based
on the CRE-Lox system44 was used to enable the deletion of the
ILK gene. A double transgenic mouse colony was established by
crossing a mouse in which LoxP sites flank the ILK gene, with a
mouse in which the Cre-recombinase gene was placed under the
control of the Mx1 promoter. Upon intraperitoneal injection with
Poly(I)-Poly(C) (pIpC), an antiviral-type response causes interferon-
mediated activation of the Mx1 promoter and subsequent produc-
tion of Cre-recombinase.44 This results in the site-specific recombi-
nation of LoxP sites and consequent removal of the ILK gene.
Platelets have a rapid turnover and immunoblot analysis of platelet
whole cell lysate indicated that 8 days after pIpC injection ILK
protein was undetectable (Figure 1A). When the ILK-deficient
(ILK(lox/lox):MxCre) and control (ILK(/):MxCre) litter mates
Figure 1. Aggregation is attenuated in ILK-deficient platelets. The levels of ILK
protein in control (Ctrl) ILK(/):MxCre and KO mice ILK(lox/lox):MxCre at 8 days
after pIpC injection were assessed by immunoblotting, and a GAPDH reprobe was
used to check for equal loading (A). Platelet counts in whole blood from control (Ctrl)
and KO are plotted (B; n 	 4, P 	 .98). Washed platelets from ILK KO and control
(Ctrl) mice were stimulated with collagen at a final concentration of 100 g/mL.
A representative aggregation trace is shown (C), and the percentage aggregation is
plotted from 3 replicate experiments (D; n 	 3, mean 
 SEM; ***P  .005). Platelets
in PRP from ILK KO and control (Ctrl) mice were matched for platelet number and
stimulated with collagen at a final concentration of 100 g/mL and monitored for
5 minutes. A representative aggregation trace is shown (E), and the percentage
aggregation (where the control 	 100%) is plotted from 3 replicate experiments
(F; n 	 3, mean 
 SEM; all **P  .05).
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were injected with pIpC, the mice showed no noticeable deteriora-
tion in health over the 8-day period.
Characterization of ILK-deficient platelets
Blood from pIpC-injected control and ILK KO mice contained an
equal number of platelets (Figure 1B). Platelet size was assessed by
flow cytometry, no difference was detected between control and
KO platelets (average diameter, 2.09 and 2.07 m, respectively),
although a small difference was noted from the non–pIpC-injected
WT mice tested (average diameter, 2.12 m). Due to their
fundamental role in the functional responses of platelets, the levels
of key adhesion receptors 2, 1, 3, IIb integrin subunits and
GPVI levels were verified in the control and KO mouse platelets
along with key integrin and ILK-binding partners. When ILK-
deficient platelets were compared with the control mice, no
significant difference was observed in levels of 2, 3, IIb
integrin subunits, GPVI levels, or the levels of integrin-associated
proteins kindlin and talin (Table 1). A modest reduction in the
levels of 1 integrin subunit was observed (13.28% 
 2.02%,
P  .05) and the expression levels of the ILK-binding partners
PINCH1 and -parvin were reduced in ILK-deficient platelets (by
66.8% 
 10.3% and 38.6% 
 8.9%, respectively, P  .05; Table
1). Previous reports show that initially pIpC-injected mice suffer
from thrombocytopenia, although platelet numbers are recovered
by around day 6.45 The experiments described in this paper were
carried out at 8 days after pIpC injection, and equivalent platelet
numbers in KO and control littermates were observed (Figure 1B).
Aggregation is attenuated in ILK-deficient platelets
The effect of ILK deficiency on platelet function was assessed.
Aggregation in response to collagen was measured in ILK-deficient
platelets and compared with sibling-matched control mouse plate-
lets (Ctrl). In washed platelets aggregation was reduced substan-
tially in the ILK-deficient platelets in comparison to controls
at both low (10 g/mL, not shown) and high concentrations
(100 g/mL) of collagen over 90 seconds (46% 
 5.6% reduction,
Figure 1C,D). This defect could not be rescued by the presence of
plasma components since aggregation responses in PRP were also
reduced substantially (54% 
 8.3% reduction; Figure 1E,F) at
90 seconds and continued to be reduced over 5 minutes
(16.9% 
 9.4% reduction; Figure 1E,F).
ILK is required for the up-regulation of integrin IIb3 function
ILK is known to associate with the cytoplasmic tail of the 1- and
3-containing integrins. To determine whether the loss of ILK
would affect the surface exposure of integrins, surface 21 and
IIb3 levels were measured by flow cytometry. In ILK-deficient
platelets 21 surface exposure was unaffected compared with
control mice (data not shown). Surface IIb3 was reduced
compared with control platelets in resting conditions (a 20%
decrease; Figure 2A). Upon activation the surface exposure of
IIb3 was increased but to a lesser extent than the control mice
(Figure 2B). This resulted in a 35% decrease in the amount of
surface IIb3, indicating that the level of recruitment of IIb3 to
the surface is reduced in the absence of ILK.
The up-regulation in affinity of IIb3 was monitored by flow
cytometry to measure the binding of FITC-labeled fibrinogen to the
platelet surface. Following stimulation with collagen or thrombin, a
large increase in fibrinogen binding to control platelets was
observed. ILK-deficient platelets, however, displayed only a small
increase in fibrinogen binding (Figure 2C,E). The large reduction in
fibrinogen binding in the ILK-deficient platelets was still apparent
when data were normalized to account for the difference in receptor
numbers (Figure 2E), indicating that ILK is involved in the
up-regulation of the affinity of IIb3. A small increase in
fibrinogen binding upon activation was, however, observed in the
ILK-deficient platelets, indicating that either low-level integrin
affinity up-regulation is possible in the absence of ILK or that
residual ILK expression is maintained below the level of detection.
Similar data obtained in response to both collagen and thrombin
Table 1. Characterization of the ILK-deficient platelets
Protein
Level detected in the KO as
a percentage of Ctrl
2 99.15 
 7.62
IIb 106.03 
 16.25
1 86.72 
 2.02*
3 94.65 
 4.38
GPVI 103.15 
 8.20
PINCH 34.21 
 10.30*
-parvin 61.36 
 8.92*
Kindlin 105 
 5.54
Talin 86.54 
 6.38
Relative levels of key adhesion receptors in the KO platelets compared to control
were determined by immunoblotting. Densitometric data are expressed as a
percentage of the control following adjustment for equivalent protein levels using
GAPDH (35 kDa).
*Mean plus or minus SEM, n	 3-8; *P .05.
Figure 2. ILK is required for the up-regulation of integrin IIb3 function. The
exposure of integrin IIb3 on the platelet surface was measured by flow cytometry in
resting platelets (A; **P  .01), and thrombin-stimulated platelets (B; ***P  .01).
Fibrinogen binding was assessed in the ILK-deficient and control (Ctrl) platelets using
FITC-labeled fibrinogen and flow cytometry. Platelets were stimulated with either
collagen (C; *P  .05) or thrombin (D; ***P  .005) (average reduction of 60% in the
KO compared with the WT). Data for fibrinogen binding upon thrombin activation was
normalized to account for the reduction in surface receptors (E). All data expressed
as mean plus or minus SEM, n 	 4.
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stimulation shows that ILK is involved in features of platelet
activation common to both agonists.
Granule secretion is defective in ILK-deficient mice
The aggregation of washed platelets is dependent upon platelet
granule secretion, which supplies fibrinogen that supports aggrega-
tion. Therefore the observed reduction in aggregation may be
explained by a reduction in either integrin affinity or secretion, or a
combination of both of these. After platelet stimulation with
collagen the secretion of -granules was assessed by monitoring
the increase in surface P-selectin by flow cytometry. In control
platelets collagen stimulated a dramatic increase in surface P-
selectin, consistent with previous reports.46 ILK-deficient platelets,
however, displayed substantially reduced surface P-selectin expo-
sure following stimulation compared with controls (Figure 3A),
while immunoblot analysis demonstrated that total P-selectin levels
are unaltered in the ILK-deficient platelets (Figure 3B). To
establish whether this was due to a defect in membrane assemblage
into the -granules or a secretion defect, the release of platelet
factor 4 (PF4) was assessed. PF4 secretion was reduced in the
ILK-deficient platelets when stimulated with collagen and throm-
bin (Figure 3C), consistent with an -granule secretion defect.
Furthermore, TEM analysis illustrated that the ILK-deficient
platelets have normal ultrastructure, including the formation of
-granules (Figure 3D,E) that appear of normal size and number
(control mean 	 3.1 
 0.57 -granules/platelet, KO mean 	
3.3 
 0.40 -granules/platelet). This reduction in -granule secre-
tion is consistent with the observed reduced recruitment of IIb3
to the platelet surface in the ILK-deficient platelets (Figure 2A,B)
and indicates the presence of a major defect in secretion in the
ILK-deficient platelets (Figure 3B).
Dense granule secretion was examined using radiolabeled
5-hydroxytryptamine (5-HT). The analysis of collagen (100 g/
mL (not shown) and 10 g/mL [Figure 3D]) and thrombin
(5 units/mL [Figure 3D]) mediated release of 5-HT revealed no
difference between control and ILK-deficient platelets (Figure 3D),
Figure 3. -granule but not dense granule secretion is
defective in ILK-deficient mice. The exposure of P-
selectin at the platelet surface was measured by flow
cytometry in resting (basal) and stimulated (collagen
100g/mL) platelets (A; mean 
 SEM, n 	 4; ***P  .005).
Western analysis of total cellular P-selectin (140 kDa) is
shown in panel B. Densitometric analysis shows the protein
levels of P-selectin are unchanged in the absence of ILK
(n 	 3, KO 	 85.77% 
 5.54%). Equivalent levels of pro-
tein loading were demonstrated by reprobing blots for
GAPDH (B, bottom panel) (35 kDa). Release of platelet
factor 4 (PF4) was measured in washed platelets stimu-
lated with collagen (10 g/mL) and thrombin (5 units/mL; C;
mean 
 SEM, n 	 4; *P  .05). Washed platelets loaded
with [3H] 5-HT were stimulated with collagen (10 g/mL)
(n 	 3, P 	 .64) and thrombin (5 units/mL; P 	 .69; D) as a
measure of dense granule secretion. TEM images of
control (Ctrl; E) and KO (F) washed mouse platelets show
normal formation of mitochondria (letter M), dense granules
(letter D), -granule (letter A), and glycerol stores (letter G)
in the KO platelets.
A DUAL ROLE FOR ILK IN PLATELETS 4527BLOOD, 1 DECEMBER 2008  VOLUME 112, NUMBER 12
indicating that dense granule secretion is unaffected by ILK
depletion. Thus, the observed reduction in aggregation is not due to
reduced secretion of dense granule components such as adenosine
diphosphate (ADP) that would normally perpetuate activation.
Thrombus formation is diminished in ILK-deficient blood
The effect of ILK depletion on thrombus formation under arterial
flow conditions was assessed in an in vitro system. Whole blood
labeled with DiOC6 was perfused through a collagen-coated
capillary at an arterial shear rate of 1000 s1 and the resulting
thrombi assessed by confocal microscopy. In the ILK-deficient
samples the number of thrombi formed was found not to be altered
(Figure 4C), indicating that the level of initial adhesion is
unaffected by the absence of ILK in platelets (Figure 4A,C).
A decrease was observed, however, in the depth of thrombi formed
in the ILK-deficient blood compared with the control samples
(Figure 4B). This suggests that the assembly of large thrombi by
platelet-platelet interactions was reduced (Figure 4A,B). This is
consistent with the expected consequences of reduced -granule
secretion (Figure 3A) and reduced collagen-stimulated IIb3
affinity up-regulation in ILK-deficient platelets (Figure 2C,D).
Mice with ILK-deficient platelets show extended bleeding
To examine the effect of ILK depletion in platelets on hemostasis,
tail bleeding assays were performed. Bleeding time and volume
was prolonged moderately in ILK-deficient mice in comparison to
the litter-mate controls, with almost all of the KO mice bleeding
beyond the 10-minute duration of the assay (Figure 5).
Early agonist-induced signaling is unaffected by the absence
of ILK
PLC2 tyrosine phosphorylation and calcium release precede both
aggregation and -granule secretion in collagen-stimulated (GPVI)
signaling. To determine whether agonist induced signaling is
initiated normally in ILK-deficient platelets, PLC2 tyrosine
phosphorylation and calcium mobilization levels were examined.
PLC2 was immunoprecipitated from resting and collagen-
stimulated (100 g/mL for 90 seconds) platelets and immunoblot-
ted for tyrosine phosphorylation and total PLC2 levels. PLC2
tyrosine phosphorylation (Figure 6A,B) was unaltered in the
ILK-deficient platelets compared with the controls. Calcium mobi-
lization was observed by loading resting platelets with Fluo4-AM
and measuring the change in fluorescence upon stimulation with
CRP. Calcium mobilization (Figure 6C) was unaltered in the
ILK-deficient platelets compared with controls. This demonstrated
that early GPVI stimulated signaling leading to calcium mobiliza-
tion was unaffected by ILK depletion (Figure 6).
Discussion
Previous work has shown that ILK physically interacts with 1 and
3 integrin subunits in platelets and that these interactions are
increased upon platelet activation.2,14,32 Since these integrins play a
major role in platelet function, adhering platelets to sites of damage
and facilitating platelet-platelet interactions, it has been proposed
that this association may be important to platelet function.2,14
Furthermore, it has been shown that ILK isolated from platelets
exhibits kinase activity that is increased transiently upon collagen
and thrombin stimulation.2
To allow analysis of the role of ILK in platelet function and
signaling, a conditional ILK knockout mouse model was estab-
lished using the Cre-LoxP system. By day 8 following Cre-
induction, ILK expression was reduced to undetectable levels in
platelets (Figure 1A). Equivalent platelet numbers were observed
in control and ILK KO mice, and levels of receptors were relatively
unchanged in the platelets, including the integrin subunits 2, IIb
and 3, GPVI (Table 1), and P-selectin (Figure 2D). Although a
modest reduction in 1 levels was observed, the adhesion of
platelets to collagen under flow conditions was unaffected (Figure
4C). While integrin 21 function has not been the focus of this
study, preliminary experiments indicate that ILK-deficient platelets
Figure 4. Thrombus formation is diminished in ILK-deficient blood. Whole blood
from KO and control (Ctrl) mice was labeled with DiOC6 and perfused through a
collagen-coated capillary at a shear rate of 1000 s1. Representative topological and
composite (stacked) views of the thrombi formed (A) show more large thrombi are
formed in the control (Ctrl) compared with the KO, though the KO sample still shows
formation of many small plaques. (B) The average maximum depth of thrombi formed
in a field of view (mean 
 SEM, n 	 10; *P  .05). The number of thrombi formed (C)
was not significantly altered in the control and KO samples (mean 
 SEM, n 	 10;
P 	 .34).
Figure 5. Bleeding time and volume is increased in the ILK KO mice. The time to
cessation of bleeding following transection of the tail tip of ILK-deficient and
litter-matched control (Ctrl) was measured over 10 minutes. Data represent individual
mice (n 	 14) with the mean value indicated. *P  .05 (A). The volume of blood lost
was assessed and is represented for individuals. *P  .05 (B).
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are able to spread on collagen and form filopodia and lamellipodia;
however, the timing of this compared with control platelets has not
been assessed.
In other cell types ILK has been shown to bind directly to
PINCH and parvin to form a complex known as the IPP that
regulates integrin signaling17 and focal adhesion.19,22 Immunoblot
analysis revealed that the expression of both proteins was reduced
in the ILK-deficient platelets (Table 1), indicating that ILK is
required to maintain full levels of these associated proteins, thus
the phenotype may reflect the combined functions of these proteins.
ILK has also been shown to be involved in interactions between
the plasma membrane and the cytoskeleton.47 Indeed this plasma
membrane-cytoskeleton interaction with ILK has been reported to
be essential for shape change, adhesion, and spreading in other cell
types.48 We have found previously that stimulation of human
platelets with CRP or thrombin results in the translocation of ILK
from the cytoplasm to the plasma membrane where it colocalizes
with integrin subunits and the membrane skeleton.2 This movement
to the surface and possibly the movement of associated proteins is
likely to be important for ILK function. In other cell types ILK has
been shown to regulate such changes in cytoskeleton arrangement.1
We therefore examined the protein expression levels of cytoskel-
eton and integrin-associated proteins kindlin and talin that are
implicated in integrin regulation.49,50 No difference in protein
levels of kindlin or talin was observed in the ILK-deficient
platelets, although talin showed a trend toward decreased expres-
sion. This suggests that these proteins are not involved in the
functional defects observed in this study.
ILK-deficient platelets showed reduced aggregation in both
washed platelets and in PRP over 5 minutes (Figure 1C-F),
demonstrating the importance of ILK in platelet function. To begin
to assess why ILK-deficient platelets showed reduced function,
integrin IIb3 surface exposure and affinity regulation were
investigated. ILK depletion reduced slightly IIb3 surface expo-
sure (Figure 2A) despite normal levels of IIb3 expression (Table
1). This is consistent with work on a skeletal muscle-restricted
deletion of ILK that shows reduced localization of 1 integrin to
myotendinous junctions.47 The activation of IIb3 to a higher
affinity binding state for fibrinogen was reduced markedly (data
normalized for receptor numbers [Figure 2E]), although was not
completely absent (Figure 2C-E), indicating that ILK has a
significant role in IIb3 activation. Clot retraction studies indi-
cated no difference between the control and ILK-deficient platelets
(data not shown), suggesting that the reduction in IIb3 activation
is unlikely to be explained by an outside-in signaling defect.
Defective platelet aggregation could also be caused by reduced
secretion during activation. Platelet - and dense-granule secretion by
ILK-deficient platelets were therefore examined. Despite normal levels
of P-selectin protein (Figure 3B) and normal platelet ultrastructure
(Figure 3E), a dramatic reduction in agonist-induced-granule secretion
in the ILK KO platelets was revealed by examining P-selectin surface
exposure (Figure 3A) and PF4 release (Figure 3C). This defect was seen
even at high concentrations of agonists and suggests a central role for
ILK in platelet activation. Dense granule secretion, however, was
maintained at both high and low concentrations of agonist (Figure
3C,D). Taken together these results suggest that this is not a general
disruption of the structural changes that occur upon platelet activation
and that -granule secretion is specifically effected by ILK depletion.
Differential secretion of - and dense-granules from platelets via the
actin cytoskeleton has been recently reported.51 It is possible, therefore,
that ILK plays a critical role in aspects unique to-granule secretion.
The presence of fibrinogen (present in -granules and plasma)
did not rescue the reduction in aggregation observed in washed
platelets (Figure 1E,F). These data suggest that the IIb3 affinity
up-regulation defect alone would cause a reduction in function.
However, the increased lag time observed in the PRP and washed
samples containing ILK-deficient platelets (Figure 1C-F) may be
due to reduced -granule secretion and further activation resulting
from this.
The importance of ILK in thrombus generation in whole blood
was investigated by studying thrombus formation on immobilized
collagen under arterial flow conditions. The number of thrombi
formed was not reduced (Figure 4C), suggesting that initial
adhesion was not substantially affected by the absence of ILK. The
depth of thrombi formed, however, was reduced in the blood of
ILK-deficient mice (Figure 4B). This reduced thrombus growth is
consistent with the reduced platelet IIb3 activation observed
(Figure 2B). The moderately increased bleeding in ILK-deficient
Figure 6. Early agonist induced signaling is unaffected by the absence of ILK.
PLC2 immunoprecipitated from ILK-deficient and control (Ctrl) washed platelets
was prepared from resting and collagen-stimulated (100 g/mL 90 seconds)
samples. Samples were immunoblotted for tyrosine phosphorylation, stripped, and
reprobed for PLC2 loading levels, and densitometric analysis was carried out (A;
mean 
 SEM, n 	 3; P 	 .44).A representative blot of PLC2 and tyrosine phosphor-
ylation (4G10) levels is shown (B). Calcium mobilization in Fluo-4AM– labeled control
(Ctrl) and ILK-deficient platelets was monitored in a Flexstation II, and change in
fluorescence was expressed as the percentage increase in calcium from resting
levels (mean 
 SEM, n 	 3; P 	 .16; C).
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mice (Figure 5) indicates the physiological importance of ILK for
normal platelet function.
Since ILK appeared to possess a central role in the platelet
activation process, it was important to establish that cell signaling
was triggered following exposure to agonists. The phosphorylation
of PLC2 and the mobilization of calcium from internal stores
following stimulation of the collagen receptor GPVI are events
up-stream of granule secretion and integrin activation. Upon
stimulation with collagen (or CRP) both events appear unaffected
by ILK depletion (Figure 6), indicating that early collagen signal-
ing events are not dependent on the presence of ILK and that the
apparent defect in platelet signaling lies further downstream.
The changes to platelet signaling and function described here,
as a result of ILK deficiency, may be as a direct result of loss of ILK
kinase activity or ILK protein-protein interactions (or a combina-
tion of both of these). In other cells ILK has been shown to form
associations with a complex of molecules, components of which
include PINCH and parvin, that together with ILK regulate integrin
signaling17,19,22 and have been shown to be necessary for the
formation of focal adhesions.22,25 Through these and other interactions
ILK is implicated in many processes including cytoskeletal arrange-
ment1,15 cell adhesion, migration, survival, and proliferation.52 Further
work will be required to establish the basis of the defects observed in
ILK-deficient mice, and whether these result from disruption of protein
complex formation and/or kinase activity.
Our data provide compelling evidence that ILK has a role in the
regulation of platelet function and suggests a dual role for ILK in
the regulation of platelet function through the control of -granule
secretion and the affinity modulation of IIb3.
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